Study Finds CBD Associated with PTSD Symptom Reduction in Adults with PTSD

LAS VEGAS, May 14, 2019 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, is pleased to announced that its industry-dominating PlusCBD Oil™ products were used in the first study to date examining the clinical benefit of CBD for the treatment of Post-Traumatic Stress Disorder (PTSD).



The study, published in The Journal of Alternative and Complementary Medicine in April 2019, examined the effect of oral CBD administration on symptoms of PTSD in a series of 11 adult patients at an outpatient psychiatry clinic. CV Sciences provided various PlusCBD Oil products for the study; delivery systems and usage were determined by patient and provider preference. The published study can be viewed at the following link: Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series . CV Sciences was not involved in the data collection, data interpretation, the preparation of the article, or the decision to submit for publication.

CBD was given on an open-label, flexible dosing regimen to patients diagnosed with PTSD by a mental health professional. Patients also received routine psychiatric care, including concurrent treatment with psychiatric medications and psychotherapy. The length of the study was eight weeks.

From the total sample of 11 patients, 10 experienced a decrease in PTSD symptom severity. The study concluded that administration of oral CBD in addition to routine psychiatric care was associated with PTSD symptom reduction in adults with PTSD. CBD also appeared to offer relief in a subset of patients who reported frequent nightmares as a symptom of their PTSD.

“We were impressed with the improvements seen in the subjects. These findings can help inform future clinical investigations, including double blind, placebo-controlled trials, to confirm the response to CBD that was observed in this study, “ says Scott Shannon, MD, principal investigator in the study.

“CV Sciences continued commitment to furthering scientific research allows us to better understand the benefits of CBD or a wide range of indications,” said Joseph Dowling, Chief Executive Officer. “After more than 80 years of prohibition, hemp CBD research has been severely hindered, but with the passage of the 2018 Farm Bill, we are beginning to understand the clinical benefits of CBD through scientific rigor. While we recognize that dietary supplements can’t be marketed for treating disease, we are pleased to support scientific progress by providing our PlusCBD Oil™ products to researchers and look forward to continued research on the clinical benefits of CBD for patients with PTSD and other indications.”

About CV Sciences, Inc.

CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics utilizing CBD. The Company’s PlusCBD Oil™ is the top-selling brand of hemp-derived CBD on the market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

CONTACT INFORMATION:

Investor Contact:

ICR

Scott Van Winkle

617-956-6736

scott.vanwinkle@icrinc.com

Media Contact:

ICR

Cory Ziskind

646-277-1232

cory.ziskind@icrinc.com